Phase 3 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phase 3 study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phase 3 Study Today - Breaking & Trending Today

After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant

Monday, the FDA informed Mesoblast Limited (NASDAQ:MESO) that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). “We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of ....

Silviu Itescu , International Blood , While The Oncologic Drugs Advisory Committee , Mesoblast Limited , Marrow Transplant Research , Biologics License Application , Oncologic Drugs Advisory Committee , Stock Market Game , Benzinga Pro , Day Trial , After Almost , Mesoblast Phase , Children Following Stem Cell Transplant , Biologics License Application , Pediatric Patients , Phase 3 Study ,

Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021

One oral presentation and five late-breaking posters accepted NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly, today announced that it will be presenting data from two Phase 3 clinical trials: the open-label extension of the CHIASMA OPTIMAL study and the MPOWERED™ study, at the Endocrine Society’s annual meeting, ENDO 2021. The conference will be held virtually from March 20-23, 2021. Chiasma is proud to be a platinum sponsor of the conference and will have a virtual booth available where registrants can find more information. Th ....

Oral Presentation , Somatostatin Receptor , Endocrine Society , Biopharmaceutical Company , Phase 3 Study , வாய்வழி ப்ரெஸெஂடேஶந் , நாளமில்லா சமூகம் , கட்டம் படிப்பு ,

Process Begins for COVID-19 Vaccine's Emergency Use


Process Begins for COVID-19 Vaccine s Emergency Use
by Angela Mohan on 
February 22, 2021 at 11:13 AM
Dr. Reddy s has started the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of Russian vaccine candidate, Sputnik V.
As part of the review process, Dr Reddy s will present the safety profile of the Phase 2 study, and interim data of the Phase 3 study, which is expected to complete by February 21.
Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, is one of only three vaccines in the world with an efficacy of 91.6 per cent and has most authorizations granted with 26 countries globally. ....

Astrazeneca Oxford Covid , Gamaleya National Research Institute Of Epidemiology , Serum Institute Of India , Russian Direct Investment Fund , Drugs Controller General , Emergency Use Authorization , Gamaleya National Research Institute , Managing Director , Serum Institute , Preferred Greeting , Traffic Accidents , More Prone , Alarming Facts , Road Traffic Accidentsroad Accidents , Road Safetywomen More Prone , Road Ragecoronavirusindian Namaste , Covid 19 Vaccine , Sputnik V , Dr Reddy S , Safety Profile , Phase 3 Study , சீரம் நிறுவனம் ஆஃப் இந்தியா , ரஷ்ய நேரடி முதலீடு நிதி , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , அவசரம் பயன்பாடு அங்கீகாரம் , நிர்வகித்தல் இயக்குனர் ,